PROJECT

Projects

Environmental & Social Review Summary

Project Number

41947

Company Name

JOINTOWN PHARMACEUTICAL GROUP CO., LTD.

Date ESRS Disclosed

Mar 21, 2019

Country

China

Region

East Asia and the Pacific

Last Updated Date

Jul 13, 2019

Environmental Category

B - Limited

Status

Active

Previous Events

Approved : May 29, 2019
Signed : May 30, 2019
Invested : Jul 10, 2019

Sector

other

Industry

Health, Education and Life Sciences

Department

Regional Industry - MAS Asia & Pac

Project Description

Jointown Pharmaceutical Group Co., Ltd. (“Jointown” or the “company”) is a major pharmaceutical product distribution company founded in 1999 in China with its headquarter based in Wuhan province and is publicly listed on the Stock Exchange of Shanghai (600998 SHA), with 31 provincial level and 94 prefecture level pharmaceutical product distribution and logistics centers throughout China. The company procures pharmaceutical products and medical equipment, stores in its large network of logistical centers in China, to be subsequently sold to hospitals, clinics, and pharmacies throughout China, transported through its own 1700-strong truck fleet, and via 85 third-party truck fleet companies throughout China contracted by the company on an as-needed basis. As part of its logistical service offering, the company’s truck fleet also provides fee-based transportation services to other third-party pharmaceutical companies and medical entities. While product distribution constitutes the core predominant part of the company’s overall business, Jointown also owns and operates one manufacturing facility in the Beijing area (which produces diabetes and cardiovascular related medications), and one in Zibo city, Shandong province (which produces medications for mental illnesses, diabetes, and cardiovascular conditions). IFC is looking at providing debt financing to Jointown of up to RMB$1 billion to support its expansion through construction of up to 5 new product distribution centers and upgrading of 4 existing warehouses in China (the “project”).

Overview of IFC's Scope of Review

IFC’s review of this proposed investment consisted of appraising environment, health and safety (EHS), and social related information provided by the company on its facilities and operations, such as: the company’s EHS management system manuals and standard operating procedures; the company’s publicly disclosed 2015, 2016, and 2017 Corporate Social Responsibility reports; E&S and operational organizational charts; human resources (HR) policies and procedures; emergency preparedness and response plans, EHS related key performance indicators (KPIs); and occupational health and safety (OHS) assessments and procedures including those related to its fleet operations. The appraisal included site visits to the company’s Beijing logistics facility, Beijing manufacturing facility, and Wuhan logistics center in January 2019. IFC toured various sections of the facilities such as fire safety control rooms, production lines, and product storage areas; and also met with heads of facilities, engineering and facility managers, line supervisors, human resource managers, other staff with EHS related responsibilities, and front-line staff.

E & S Project Categorization and Applicable Standard

Environmental and Social Mitigation Measures

Stakeholder Engagement

Broad Community Support

Environmental & Social Action Plan